Pulmonary vein isolation alone versus pulmonary vein isolation plus linear ablation for persistent atrial fibrillation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter, open-label, randomized controlled trial that assigns adults with persistent AF 1:1 to pulmonary vein isolation (PVI) using pulsed field ablation (PFA) alone or to PVI plus planned linear ablations. The PVI-plus-linear arm includes bilateral PVI and linear lesions on the posterior wall, mitral isthmus and cavo-tricuspid isthmus, with optional ethanol infusion of the vein of Marshall (EIVOM) recommended before PFA at operator discretion. If AF cannot be terminated during the procedure, electrical cardioversion will be used. All participants are followed at discharge, at 1 month, and then every 3 months up to 12 months with rhythm monitoring to document maintenance of sinus rhythm.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Study subjects are required to meet all the following inclusion criteria:

1. Subjects with an age range of 18 years or above and 80 years or below.
2. Subjects have symptomatic, drug-resistant, persistent AF, defined as:

   1. Symptomatic: these symptoms include but not limited to palpitations, presyncope, syncope, fatigue, and shortness of breath.
   2. Drug-resistant: effectiveness failure of, intolerance to, or specific contraindication to at least one AAD.
   3. Persistent: continuous AF for \> 90 days, i) with a minimum a physician's note confirming the diagnosis AND,within 180 days of Enrollment Date, either a 24-hour or longer continuous ECG recording confirming continuous AF OR Two ECGs showing continuous AF taken at least 90 days apart.
3. Subjects undergoing a first-time ablation procedure for AF.
4. Subjects who are willing and capable of providing ICF and participating in all testing associated with this study.

Exclusion Criteria:

1. AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible/non-cardiac causes.
2. Left atrial anteroposterior diameter ≥ 6.0 cm by transthoracic echocardiography (TTE) within 3 months prior the procedure.
3. Heart failure with left ventricular ejection fraction (LVEF) \< 30% by TTE within 3 months prior the procedure.
4. LA thrombus detected by Transesophageal Echocardiography (TEE) or cardiac CT within one day before the procedure or Intracardiac Echocardiography (ICE) before atrial septal puncture during the procedure.
5. Current or anticipated pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices, mechanical valve, interatrial baffle, closure device, patch, or patent foramen oval occlude, left atrial appendage closure at the time of ablation.
6. Any of the following events within 90 days of the Consent Date:

   1. Myocardial infarction, unstable angina or coronary intervention or any cardiac surgery
   2. Pericarditis or symptomatic pericardial effusion
   3. Gastrointestinal bleeding
   4. Stroke, transient ischemic attack (TIA), or intracranial bleeding or any non-neurologic thromboembolic event
7. Contraindication to, or unwillingness to use systemic anticoagulation.
8. Subjects cannot be removed from Class I/III AAD for reasons other than atrial arrhythmia.
9. Women of childbearing potential who are pregnant or lactating.
10. Renal insufficiency if an estimated glomerular filtration rate (eGFR) is \< 30 mL/min/1.73 m2, or with any history of renal dialysis or renal transplant.
11. Conditions that in the investigator's medical opinion would interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.
12. Predicted life expectancy less than 12 months.

Where it's running

• Beijing Anzhen Hospital, affiliated to Capital Medical University
  Beijing, China Recruiting

Study contacts

• Principal investigator: Changsheng Ma, Doctor — Beijing Anzhen Hospital of the Capital University of Medical Sciences
• Study coordinator: Taimin Yue
• Email: taimin.yue@bsci.com
• Phone: 86-10-8574 2988

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FARAFLEX Mapping and Pulsed Field Ablation for Atrial Fibrillation

  This trial tests the FARAFLEX Mapping and PFA System to see if it can safely help adults with drug-refractory paroxysmal or persistent atrial fibrillation.

  Recruiting at 13 sites Boston Scientific Corporation · Jonesboro, Arkansas and 12 other locations · NCT07575269

• Pulsed field ablation for atrial fibrillation in underrepresented minority patients

  This registry will test how well Boston Scientific pulsed field ablation works and how safe it is for Black, Hispanic, Asian, and other underrepresented adults with paroxysmal or persistent atrial fibrillation.

  Recruiting at 2 sites Icahn School of Medicine at Mount Sinai · New York, New York and 1 other locations · NCT07535268

• Left Atrial Appendage Occlusion and Rhythm Restoration in AF Patients

  This trial tests a combined procedure using the Volt PFA System and Amulet 2 to see if it safely and feasibly treats atrial fibrillation while also closing the left atrial appendage in adults with AF.

  Recruiting at 13 sites Abbott Medical Devices · Brussels, B CAP R and 15 other locations · NCT07523620

• Qidong Yixin Granules to prevent atrial fibrillation returning after ablation

  This trial tests whether taking Qidong Yixin Granules after catheter ablation can lower the chance of atrial fibrillation coming back within a year in adults with persistent AF.

  Recruiting Phase 4 Sir Run Run Shaw Hospital · Hangzhou and 4 other locations · NCT07508618

• FARAPULSE pulsed-field waveform treatment for paroxysmal and persistent atrial fibrillation

  This will test new pulsed electrical waveforms delivered by the FARAPULSE PFA system to treat adults with paroxysmal or persistent atrial fibrillation.

  Recruiting at 3 sites Boston Scientific Corporation · Split and 3 other locations · NCT07444320

• PVI Alone vs PVI Plus PWI and SVCI with PFA in Persistent AF

  This study tests whether adding posterior wall isolation and superior vena cava isolation to pulmonary vein isolation with pulsed-field ablation helps people with persistent atrial fibrillation stay in rhythm.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07405359

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.